The once-daily oral drug has been cleared under the Veozah brand name for moderate to severe vasomotor symptoms (commonly known as hot flashes) in menopausal women, becoming a non-hormonal ...
The company hasn’t given a timeline for those regulatory filings but will no doubt want to move quickly as it chases after Astellas, which claimed approval for NK 3 antagonist Veozah ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback